Biomarkers of gastric cancer: current advancement

• Published in: Heliyon Vol. 8; no. 10; p. e10899
• Main Authors: Jiang, Tiantian, Mei, Lin, Yang, Xiao, Sun, Tingkai, Wang, Zhidong, Ji, Yuanyuan
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.10.2022; Elsevier
• Subjects: Biomarkers; Diagnosis; Gastric cancer; Liquid biopsies; Prognosis; Review; Liquid biopsies; Biomarkers; Prognosis; Diagnosis; Gastric cancer
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2022.e10899

Gastric cancer (GC) is one of the most prevalent malignant types worldwide, especially in East Asia. Due to its frequently advanced stage at diagnosis, the mortality from GC is high and the prognosis is still unsatisfactory. Thus, early detection using effective screening approaches is vital to decrease the morbidity and mortality of GC. Interestingly, biomarkers can be used for diagnosis, prediction of sensitivity to treatment, and prognosis in GC. The potential biomarkers detectable in liquid biopsies such as circulating tumor cells (CTCs), long non-coding RNAs (lncRNAs), cell-free DNA (cfDNA), microRNAs, and exosomes reveal numerous information regarding the early prediction and the outcomes for GC patients. Additionally, using the novel serum biomarkers has opened up new opportunities for diagnosing and monitoring patients with GC. This review mainly summarizes the novel progress and approaches in GC biomarkers, which could be potentially used for early diagnosis and therapy monitoring. Meanwhile, we also discussed the advantages, disadvantages, and future perspectives of GC biomarkers. Gastric cancer; Diagnosis; Prognosis; Liquid biopsies; Biomarkers.